Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED)

被引:0
作者
Aileen Sy
Kieran S. O’Brien
Margaret P. Liu
Puja A. Cuddapah
Nisha R. Acharya
Thomas M. Lietman
Jennifer Rose-Nussbaumer
机构
[1] Department of Ophthalmology,F.I. Proctor Foundation
[2] California Pacific Medical Center,Department of Ophthalmology
[3] University of California,undefined
[4] University of California,undefined
来源
BMC Ophthalmology | / 15卷
关键词
Dry eye disease; Keratoconjunctivitis sicca; Sjögrens;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 189 条
[1]  
Um SB(2014)Spatial epidemiology of dry eye disease: findings from South Korea Int J Health Geogr 13 31-100
[2]  
Kim NH(2012)Dry eye disease: an immune-mediated ocular surface disorder Arch Ophthalmol 130 90-342
[3]  
Lee HK(2004)Antiinflammatory therapy for dry eye Am J Ophthalmol 137 337-949
[4]  
Song JS(2012)Clinical treatment of dry eye using 0.03 % tacrolimus eye drops Cornea 31 945-52
[5]  
Kim HC(2004)Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease Br J Ophthalmol. 88 647-1252
[6]  
Stevenson W(2011)Treatment of Sjogren’s syndrome-associated dry eye an evidence-based review Ophthalmology 118 1242-57
[7]  
Chauhan SK(2004)A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5 %, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance Am J Ophthalmol 138 444-974
[8]  
Dana R(2000)Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group Ophthalmology 107 967-639
[9]  
Pflugfelder SC(2000)Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group Ophthalmology 107 631-1794
[10]  
Moscovici BK(2005)Phase III safety evaluation of cyclosporine 0.1 % ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years Ophthalmology 112 1790-1104